Clinical Trials Logo

Clinical Trial Summary

A prospective imaging and translational tissue study in CNS lymphoma to enable further disease characterisation and the development of potential predictive and prognostic biomarkers.


Clinical Trial Description

As a single centre exploratory study, this trial will recruit patients with newly diagnosed primary CNS lymphoma and will look at the molecular aspects of the disease in the tissue collection and imaging response assessments using CCA with respect to progression free survival. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05828628
Study type Observational
Source Royal Marsden NHS Foundation Trust
Contact Rachel Powell
Phone 0203 186 5176
Email rachel.powell@rmh.nhs.uk
Status Not yet recruiting
Phase
Start date June 2023
Completion date June 2031

See also
  Status Clinical Trial Phase
Recruiting NCT05117814 - Zanubrutinib Monotherapy in Relapsed/Refractory Central Nervous System Lymphoma N/A
Terminated NCT05222269 - [68Ga]Ga-PentixaFor PET Imaging in CNS Lymphoma Patients Phase 2
Recruiting NCT06132737 - [90Y]Y-PTT Endoradiotherapy in CNS Lymphoma Patients Phase 1/Phase 2
Terminated NCT05242146 - GB5121 in Adult Patients With Relapsed/Refractory CNS Lymphoma Phase 1
Completed NCT01319591 - Comparison of Creatinine Clearance Calculation for Estimation of GFR in Patients Receiving HD Methotrexate
Recruiting NCT06322342 - Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent Phase 2
Recruiting NCT05351593 - Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma Phase 1/Phase 2
Completed NCT01182415 - High Dose Chemotherapy and Stem Cell Transplant for Non-Hodgkin's Lymphoma or Central Nervous System (CNS) Lymphoma Phase 2
Not yet recruiting NCT06343311 - T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) Phase 1/Phase 2
Recruiting NCT04841434 - A Phase I/II Study to Investigate the Use of VORAXAZEâ„¢ as Intended Intervention in Patients With CNSL Phase 1/Phase 2
Completed NCT01083342 - High-Dose (HD) Methotrexate (MTX) Induction Chemotherapy Followed by Alternative HD MTX-based and HD Cytarabine-based Combination Consolidation Chemotherapy for Newly Diagnosed Primary CNS Lymphoma; CISL 10-01 Study Phase 2
Completed NCT05293990 - Usefulness of Gadovist-enhanced FLAIR Imaging N/A
Completed NCT00596154 - Rituximab, Methotrexate, Procarbazine and Vincristine Followed by High-dose Chemotherapy With Autologous Stem-cell Rescue in Newly-diagnosed Primary CNS Lymphoma Phase 2
Recruiting NCT05926427 - Orelabrutinib Combined With Rituximab and Chemotherapy for Relapsed/Refractory B-Cell Lymphoma Patients With Central Nervous System Involvement Phase 2